| Peptide therapeutics: current status and future directions K Fosgerau, T Hoffmann Drug discovery today 20 (1), 122-128, 2015 | 3037 | 2015 |
| Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis MB Pepys, J Herbert, WL Hutchinson, GA Tennent, HJ Lachmann, ... Nature 417 (6886), 254-259, 2002 | 640 | 2002 |
| Immune versus natural selection: antibody aldolases with enzymic rates but broader scope CF Barbas III, A Heine, G Zhong, T Hoffmann, S Gramatikova, ... Science 278 (5346), 2085-2092, 1997 | 485 | 1997 |
| Aldolase antibodies of remarkable scope T Hoffmann, G Zhong, B List, D Shabat, J Anderson, S Gramatikova, ... Journal of the American Chemical Society 120 (12), 2768-2779, 1998 | 310 | 1998 |
| Antibody-catalyzed enantioselective Robinson annulation G Zhong, T Hoffmann, RA Lerner, S Danishefsky, CF Barbas Journal of the American Chemical Society 119 (34), 8131-8132, 1997 | 199 | 1997 |
| The next level in chemical space navigation: going far beyond enumerable compound libraries T Hoffmann, M Gastreich Drug Discovery Today, 2019 | 184 | 2019 |
| Pharmaceutical formulations and method for making T Hoffmann, M Pieroth, G Zessin, KF Landgraf US Patent App. 09/793,936, 2002 | 113 | 2002 |
| Peptide-based in vivo siRNA delivery system DB Rozema, DH Wakefield, DL Lewis, JA Wolff, AV Blokhin, JD Benson, ... US Patent 8,501,930, 2013 | 101 | 2013 |
| Biopolymers, and Oligomers of (R)-3-hydroxyalkanoic Acids—Contributions of Synthetic Organic Chemists D Seebach, A Brunner, BM Bachmann, T Hoffmann, FNM Kühnle, ... Berlin: Ernst Schering Research Foundation, 1995 | 84 | 1995 |
| Influence of drying conditions on layer porosity in fluidized bed spray granulation C Rieck, T Hoffmann, A Bück, M Peglow, E Tsotsas Powder Technology 272, 120-131, 2015 | 79 | 2015 |
| Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA P Hadwiger, T Hoffmann, EA Kitas, P Mohr, I Roehl, L Valis, DB Rozema, ... US Patent 9,249,179, 2016 | 73 | 2016 |
| 4-phenyl-pyridine derivatives M Bös, Q Branca, G Galley, T Godel, T Hoffmann, W Hunkeler, P Schnider, ... US Patent 6,297,375, 2001 | 66 | 2001 |
| 4-phenyl-pyridine derivatives M Bös, Q Branca, G Galley, T Godel, T Hoffmann, W Hunkeler, P Schnider, ... US Patent 6,479,483, 2002 | 64 | 2002 |
| Compositions for targeted delivery of siRNA DB Rozema, DL Lewis, DH Wakefield, T Hoffmann, E Kitas, P Mohr, ... US Patent 9,011,919, 2015 | 63 | 2015 |
| Peptide-based in vivo siRNA delivery system DB Rozema, DL Lewis, D Wakefield, E Kitas, P Hadwiger, J Wolff, I Röhl, ... US Patent 9,107,957, 2015 | 62 | 2015 |
| Small molecule conjugates for intracellular delivery of biologically active compounds P Hadwiger, T Hoffmann, K Jahn-Hofmann, EA Kitas, DL Lewis, P Mohr, ... US Patent 9,301,990, 2016 | 59 | 2016 |
| NK-1 receptor active amine oxide prodrugs T Hoffmann, SM Poli, P Schnider, A Sleight US Patent 6,593,472, 2003 | 57 | 2003 |
| Small molecule conjugates for intracellular delivery of nucleic acids P Hadwiger, T Hoffmann, K Jahn-Hofmann, EA Kitas, DL Lewis, P Mohr, ... US Patent 9,198,947, 2015 | 54 | 2015 |
| Preparation and Structure of Oligolides from (R)‐3‐Hydroxypentanoic Acid and comparison with the hydroxybutanoic‐acid derivatives: A small change with large … D Seebach, T Hoffmann, FNM Kühnle, UD Lengweiler Helvetica chimica acta 77 (7), 2007-2034, 1994 | 51 | 1994 |
| Design and synthesis of a novel, achiral class of highly potent and selective, orally active neurokinin-1 receptor antagonists T Hoffmann, M Bös, H Stadler, P Schnider, W Hunkeler, T Godel, G Galley, ... Bioorganic & medicinal chemistry letters 16 (5), 1362-1365, 2006 | 50 | 2006 |
